326P - Tumor heterogeneity in 18F-FDG PET/CT as a biomarker for prediction of treatment response and locoregional recurrence in patients with pharyngeal c...

Date 20 December 2015
Event ESMO Asia 2015 Congress
Session Poster presentation 2
Topics Anti-Cancer Agents & Biologic Therapy
Head and Neck Cancers
Translational Research
Surgery and/or Radiotherapy of Cancer
Presenter YOUNG MI Seol
Citation Annals of Oncology (2015) 26 (suppl_9): 93-102. 10.1093/annonc/mdv527
Authors Y.M. Seol1, J.Y. Jang2, K. Park3, Y.J. Choi4
  • 1Hematology-oncology, Pusan National University Hospital, 602-739 - Busan/KR
  • 2Otorhinolaryngology-head And Neck Surgery, Pusan National University Hospital, Busan/KR
  • 3Nuclear Medicine, Pusan National University Hospital, Busan/KR
  • 4Hematology-oncology, Pusan National University Hospital, Busan/KR

Abstract

Aim/Background

This study aimed to explore the predictive value of intratumoral heterogeneity of 18F-FDG uptake in pharyngeal cancer treated with chemoradiotherapy.

Methods

These analyses included 52 consecutive patients with pharyngeal cancer who underwent 18F-FDG PET/CT before definitive chemoradiotherapy. The heterogeneity factor (HF) was defined as the derivative (dV/dT) of a volume-threshold function for a primary tumor and metastatic lymph nodes, respectively. The relationships between clinical parameters and HF in primary tumor (pHF) and metastatic lymph nodes (nHF) were analyzed.

Results

The HF ranged from -1.367 to -0.027 (median -0.152) in primary tumor. The pHF was significantly correlated with SUVmax, metabolic tumor volume, total lesion glycolysis. Response to induction chemotherapy was not correlated with pHF while response to radiotherapy was significantly better in patients with high pHF (low heterogeneity). Consistently, the 2-year locoregional recurrence-free survival was significantly better in patients with high pHF (82.9% in -0.152 < pHF versus 30.5% in -0.152 > pHF, log-rank p = 0.009). However, nHF (ranged from -1.067 to -0.039 (median -0.160)) was not significantly correlated with response to radiotherapy and locoregional recurrences.

Conclusions

The pHF was a significant predictive value of radiation response and locoregional recurrence in pharyngeal cancer while nHF was not a significant predictive factor.

Clinical trial identification

Disclosure

All authors have declared no conflicts of interest.